Nalbuphine

CHEMBL895 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
357.4 g/mol
LogP
0.2
Phase
4

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Khối lượng phân tử

357,4000 g/mol

LogP

0,20

TPSA

73,20 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314

InChI

InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1

Molecular Formula

C21H27NO4

HBD / HBA

3 / 5

Liên kết có thể quay

2

Nguyên tử nặng

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Nalbuphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL895. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5311304. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.